Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Prostaglandins Leukot Essent Fatty Acids. 2009 Oct 22;81(5-6):357–366. doi: 10.1016/j.plefa.2009.09.004

Figure 7. Benzo-LXA4 activation of the ALX-FPR2 GPCR.

Figure 7

A) Dose dependent increase in phagocytosis. Phagocytosis, determined as indicated in Materials and Methods, from resident murine peritoneal macrophages treated with the indicated concentrations of o-[9,12]-benzo-ω6-epi-LXA4 (▼) or LXA4 (■) (15 min, 37 °C) followed by co-incubation with FITC-labeled zymosan A (30 min, 37°C). Values represent mean ± SEM, n = 3; *, P<0.05 when compared with vehicle; †, P<0.05 when compared with LXA4.

B) Ligand dependent activation of ALX-FPR2 receptor. HEK-ALX β-arrestin cells (see text for details) were exposed to the indicated concentration of 15-epi-LXA4 (●) or o-[9,12]-benzo-ω6-epi-LXA4 (▼) (1h, 37 °C) followed by incubation with the β-galactosidase substrate (1h, 21 °C). Values are relative luminescence unit subtracted from background (mean ± SEM, n = 3-5; RLU, relative luminescence unit).